Document series

Trial abstracts — page 4

700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.

Filter by text

Phase

Status

Showing 0 records on this page

Trial records

700 documents · page 4 of 30

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

Record	Compound	Phase	Status	Design	Randomised	Year	Certainty
HARMONY-OUTCOMES	Dulaglutide	Phase 3	Reported	Event-driven cardiovascular outcome trial	9,463	2018	Moderate
MMPOWER-2	SS-31 (elamipretide)	Phase 2	Reported	Randomised crossover	30	2018	Moderate
SUSTAIN-7	Semaglutide	Phase 3	Reported	Randomised, double-blind, active-controlled	1,201	2018	High
EXSCEL	Exenatide	Phase 3	Reported	Event-driven cardiovascular outcome trial	14,752	2017	High
GSH-PD-PH2	Glutathione	Phase 2	Reported	Randomised, double-blind, placebo-controlled	45	2017	Low
KISS-PH2-HSDD	Kisspeptin-10	Phase 2	Reported	Randomised crossover	32	2017	Low
SCALE-PREDIABETES	Liraglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	2,254	2017	Moderate
SUSTAIN-1	Semaglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	388	2017	High
ADJUNCT-ONE	Liraglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	1,398	2016	Moderate
ADJUNCT-TWO	Liraglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	835	2016	Moderate
EMBRACE-STEMI	Exenatide	Phase 2	Reported	Randomised, double-blind, placebo-controlled	91	2016	Moderate
LEADER	Liraglutide	Phase 3	Reported	Event-driven cardiovascular outcome trial	9,340	2016	High
LIVERAGE	Liraglutide	Phase 2	Reported	Randomised, double-blind, placebo-controlled	52	2016	Low
SCALE-SLEEP-APNOEA	Liraglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	359	2016	Moderate
SUSTAIN-6	Semaglutide	Phase 3	Reported	Event-driven cardiovascular outcome trial	3,297	2016	High
TB4-PH2-EPIDERMOLYSIS	Thymosin beta-4	Phase 2	Reported	Randomised, double-blind, placebo-controlled	30	2016	Low
AOD-OA-PH2	AOD-9604	Phase 2	Reported	Randomised, double-blind, placebo-controlled	—	2015	Low
CELIAC-PH2B	Larazotide acetate	Phase 2b	Reported	Randomised, double-blind, placebo-controlled	342	2015	Moderate
ELIXA	Lixisenatide	Phase 3	Reported	Event-driven cardiovascular outcome trial	6,068	2015	High
SCALE-OBESITY	Liraglutide	Phase 3	Reported	Randomised, double-blind, placebo-controlled	3,731	2015	High
TB4-PH2-DRYEYE	Thymosin beta-4	Phase 2	Reported	Randomised, double-blind, placebo-controlled	72	2015	Low
AWARD-1	Dulaglutide	Phase 3	Reported	Randomised, double-blind, active-controlled	976	2014	High
AWARD-5	Dulaglutide	Phase 3	Reported	Randomised, double-blind, active-controlled	1,098	2014	High
AWARD-6	Dulaglutide	Phase 3	Reported	Randomised, open-label, active-controlled	599	2014	High

page 4 of 30